IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i8p2831-d348078.html
   My bibliography  Save this article

Lifetime Costs of Surviving Cancer—A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study

Author

Listed:
  • Katharina M. D. Merollini

    (Sunshine Coast Health Institute, School of Health and Sport Sciences, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia)

  • Louisa G. Gordon

    (QIMR Berghofer, Medical Research Institute, Herston, QLD 4006, Australia
    School of Nursing, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia
    School of Public Health, The University of Queensland, Herston, QLD 4006, Australia)

  • Joanne F. Aitken

    (Cancer Council Queensland, Fortitude Valley, QLD 4006, Australia
    Institute for Resilient Regions, University of Southern Queensland, Ipswich, QLD 4305, Australia
    Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD 4222, Australia)

  • Michael G. Kimlin

    (Sunshine Coast Health Institute, School of Health and Sport Sciences, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia
    School of Biomedical Sciences, Queensland University of Technology, St Lucia, QLD 4072, Australia)

Abstract

Australia-wide, there are currently more than one million cancer survivors. There are over 32 million world-wide. A trend of increasing cancer incidence, medical innovations and extended survival places growing pressure on healthcare systems to manage the ongoing and late effects of cancer treatment. There are no published studies of the long-term health service use and cost of cancer survivorship on a population basis in Australia. All residents of the state of Queensland, Australia, diagnosed with a first primary malignancy from 1997–2015 formed the cohort of interest. State and national healthcare databases are linked with cancer registry records to capture all health service utilization and healthcare costs for 20 years (or death, if this occurs first), starting from the date of cancer diagnosis, including hospital admissions, emergency presentations, healthcare costing data, Medicare services and pharmaceuticals. Data analyses include regression and economic modeling. We capture the whole journey of health service contact and estimate long-term costs of all cancer patients diagnosed and treated in Queensland by linking routinely collected state and national healthcare data. Our results may improve the understanding of lifetime health effects faced by cancer survivors and estimate related healthcare costs. Research outcomes may inform policy and facilitate future planning for the allocation of healthcare resources according to the burden of disease.

Suggested Citation

  • Katharina M. D. Merollini & Louisa G. Gordon & Joanne F. Aitken & Michael G. Kimlin, 2020. "Lifetime Costs of Surviving Cancer—A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study," IJERPH, MDPI, vol. 17(8), pages 1-16, April.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:8:p:2831-:d:348078
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/8/2831/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/8/2831/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Antoine Schernberg & Luis Sagaon-Teyssier & Michaël Schwarzinger & Sylvain Baillot & Mélina Bec & Lynda Benmahammed & Caroline Even & Lionel Geoffrois & Florence Huguet & Béatrice Le Vu & Laurie Lévy-, 2019. "Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France," Post-Print hal-02271446, HAL.
    2. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    3. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    4. Laura Delgado-Ortega & Almudena González-Domínguez & Josep María Borrás & Juan Oliva-Moreno & Eva González-Haba & Salomón Menjón & Pedro Pérez & David Vicente & Luis Cordero & Margarita Jiménez & Susa, 2019. "The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 135-147, February.
    5. Louisa G. Gordon & Katharina M. D. Merollini & Anthony Lowe & Raymond J. Chan, 2017. "A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 10(3), pages 295-309, June.
    6. S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen, 2009. "Comparing methodologies for the cost estimation of hospital services," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 39-45, February.
    7. Nicole Bates & Emily Callander & Daniel Lindsay & Kerrianne Watt, 2018. "CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Katharina M. D. Merollini & Louisa G. Gordon & Yiu M. Ho & Joanne F. Aitken & Michael G. Kimlin, 2022. "Cancer Survivors’ Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q)," IJERPH, MDPI, vol. 19(15), pages 1-17, August.
    2. Laura C. Edney & Jackie Roseleur & Tim Bright & David I. Watson & Gaston Arnolda & Jeffrey Braithwaite & Geoffrey P. Delaney & Winston Liauw & Rebecca Mitchell & Jonathan Karnon, 2023. "DAta Linkage to Enhance Cancer Care (DaLECC): Protocol of a Large Australian Data Linkage Study," IJERPH, MDPI, vol. 20(11), pages 1-16, May.
    3. Annie Bygrave & Kate Whittaker & Christine Paul & Elizabeth A. Fradgley & Megan Varlow & Sanchia Aranda, 2021. "Australian Experiences of Out-of-Pocket Costs and Financial Burden Following a Cancer Diagnosis: A Systematic Review," IJERPH, MDPI, vol. 18(5), pages 1-19, March.
    4. Louisa G. Gordon & William Leung & Richard Johns & Bronwen McNoe & Daniel Lindsay & Katharina M. D. Merollini & Thomas M. Elliott & Rachel E. Neale & Catherine M. Olsen & Nirmala Pandeya & David C. Wh, 2022. "Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021," IJERPH, MDPI, vol. 19(6), pages 1-14, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katharina M. D. Merollini & Louisa G. Gordon & Yiu M. Ho & Joanne F. Aitken & Michael G. Kimlin, 2022. "Cancer Survivors’ Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q)," IJERPH, MDPI, vol. 19(15), pages 1-17, August.
    2. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2020. "A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 529-542, June.
    3. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    4. Louisa G. Gordon & William Leung & Richard Johns & Bronwen McNoe & Daniel Lindsay & Katharina M. D. Merollini & Thomas M. Elliott & Rachel E. Neale & Catherine M. Olsen & Nirmala Pandeya & David C. Wh, 2022. "Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021," IJERPH, MDPI, vol. 19(6), pages 1-14, March.
    5. Annie Bygrave & Kate Whittaker & Christine Paul & Elizabeth A. Fradgley & Megan Varlow & Sanchia Aranda, 2021. "Australian Experiences of Out-of-Pocket Costs and Financial Burden Following a Cancer Diagnosis: A Systematic Review," IJERPH, MDPI, vol. 18(5), pages 1-19, March.
    6. Leticia García-Mochón & Zuzana Špacírová & Jaime Espín, 2022. "Costing methodologies in European economic evaluation guidelines: commonalities and divergences," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(6), pages 979-991, August.
    7. Giovanna Elisa Calabrò & Sara Boccalini & Donatella Panatto & Caterina Rizzo & Maria Luisa Di Pietro & Fasika Molla Abreha & Marco Ajelli & Daniela Amicizia & Angela Bechini & Irene Giacchetta & Piero, 2022. "The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment," IJERPH, MDPI, vol. 19(7), pages 1-14, March.
    8. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    9. Clarke, Lorcan, 2020. "An introduction to economic studies, health emergencies, and COVID-19," LSE Research Online Documents on Economics 105051, London School of Economics and Political Science, LSE Library.
    10. Najmiatul Fitria & Antoinette D. I. Asselt & Maarten J. Postma, 2019. "Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 407-417, April.
    11. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    12. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    13. Wendy Hens & Dirk Vissers & Nick Verhaeghe & Jan Gielen & Luc Van Gaal & Jan Taeymans, 2021. "Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis," IJERPH, MDPI, vol. 18(15), pages 1-13, July.
    14. Kim Edmunds & Penny Reeves & Paul Scuffham & Daniel A. Galvão & Robert U. Newton & Mark Jones & Nigel Spry & Dennis R. Taaffe & David Joseph & Suzanne K. Chambers & Haitham Tuffaha, 2020. "Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 727-737, October.
    15. Andrew Gawron & Dustin French & John Pandolfino & Colin Howden, 2014. "Economic Evaluations of Gastroesophageal Reflux Disease Medical Management," PharmacoEconomics, Springer, vol. 32(8), pages 745-758, August.
    16. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    17. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
    18. Jesse Elliott & Sasha Katwyk & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & Becky Skidmore & George A. Wells & Doug Coyle, 2019. "Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations," PharmacoEconomics, Springer, vol. 37(10), pages 1261-1276, October.
    19. Wei Zhang & Aslam Anis, 2014. "Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now," PharmacoEconomics, Springer, vol. 32(5), pages 425-427, May.
    20. Xiao Xu & Kimberly A Yonkers & Jennifer P Ruger, 2014. "Costs of a Motivational Enhancement Therapy Coupled with Cognitive Behavioral Therapy versus Brief Advice for Pregnant Substance Users," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-10, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:8:p:2831-:d:348078. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.